Grifols

Company snapshot

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prev

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Grifols. Not investment advice.

• What is Grifols?

  Instituto Grifols is a pharma organization headquartered in EU. Primary therapeutic focus areas include Severe Alpha-1 Antitrypsin Deficiency (AATD). NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, Clinica

• Is Grifols publicly traded?

  Grifols appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Grifols develop or market?

  We link 2 drug profile(s) where Grifols is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/instituto-grifols-s-a#company-drugs.

• What are the latest developments for Grifols?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Grifols focus on?

  Grifols focuses on Severe Alpha-1 Antitrypsin Deficiency (AATD) based on our analysis of their pipeline programs and drug development activities.